Libo Sun

897 total citations
24 papers, 603 citations indexed

About

Libo Sun is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Libo Sun has authored 24 papers receiving a total of 603 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 12 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Libo Sun's work include Acute Myeloid Leukemia Research (14 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Libo Sun is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Libo Sun collaborates with scholars based in United States, Italy and France. Libo Sun's co-authors include Steve Lacroix, Dominic Bastien, Isabelle Pineau, Dan Shen, Bing Zhou, Shan Lu, Wei Li, Yu‐ming M. Huang, Yan Zeng and Qing Bao Tian and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Neurochemistry.

In The Last Decade

Libo Sun

22 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Libo Sun United States	8	189	121	117	94	85	24	603
Jonilson Berlink Lima Brazil	13	603 3.2×	145 1.2×	50 0.4×	45 0.5×	37 0.4×	22	962
Marija Mostarica‐Stojković Serbia	20	255 1.3×	28 0.2×	236 2.0×	47 0.5×	107 1.3×	41	1.1k
Anuradha Tarafdar United Kingdom	14	280 1.5×	28 0.2×	36 0.3×	19 0.2×	49 0.6×	25	748
Varun Kesherwani United States	16	319 1.7×	25 0.2×	48 0.4×	55 0.6×	31 0.4×	28	611
Monika Linke Austria	6	442 2.3×	25 0.2×	42 0.4×	26 0.3×	45 0.5×	7	1.0k
Nathalie Paul‐Eugène France	18	205 1.1×	57 0.5×	47 0.4×	94 1.0×	25 0.3×	37	891
Ying Fu United States	20	563 3.0×	84 0.7×	14 0.1×	67 0.7×	164 1.9×	31	1.2k
Hiroto Yamamoto Japan	13	216 1.1×	19 0.2×	36 0.3×	51 0.5×	47 0.6×	32	610
Alice N. McEvoy Ireland	14	143 0.8×	106 0.9×	19 0.2×	220 2.3×	53 0.6×	17	762
Sinéad M. Miggin Ireland	18	509 2.7×	26 0.2×	24 0.2×	90 1.0×	52 0.6×	25	1.2k

Countries citing papers authored by Libo Sun

Since Specialization

Citations

This map shows the geographic impact of Libo Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Libo Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Libo Sun more than expected).

Fields of papers citing papers by Libo Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Libo Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Libo Sun. The network helps show where Libo Sun may publish in the future.

Co-authorship network of co-authors of Libo Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Libo Sun. A scholar is included among the top collaborators of Libo Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Libo Sun. Libo Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Libo, Fei Huang, Robert Kleiman, et al.. (2025). Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis. Clinical and Translational Science. 18(2). e70169–e70169.

Huang, Fei, Ying Wan, Libo Sun, et al.. (2024). Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science. Clinical and Translational Science. 17(11). e70076–e70076. 12 indexed citations

Huang, Fei, Ying Wan, Libo Sun, et al.. (2024). Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor. CPT Pharmacometrics & Systems Pharmacology. 13(7). 1264–1277. 4 indexed citations

Sekeres, Mikkael A., Valeria Santini, María Díez‐Campelo, et al.. (2024). Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study. Leukemia & lymphoma. 66(3). 529–534. 2 indexed citations

Komrokji, Rami S., Valeria Santini, Pierre Fenaux, et al.. (2023). Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study. Blood. 142(Supplement 1). 194–194. 1 indexed citations

Sekeres, Mikkael A., María Díez‐Campelo, Amer M. Zeidan, et al.. (2023). Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial. Blood. 142(Supplement 1). 6479–6479.

Zeidan, Amer M., Uwe Platzbecker, Valeria Santini, et al.. (2023). IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).. Journal of Clinical Oncology. 41(16_suppl). 7004–7004. 4 indexed citations

Santini, Valeria, Amer M. Zeidan, Pierre Fenaux, et al.. (2023). Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study. Blood. 142(Supplement 1). 4603–4603. 1 indexed citations

Platzbecker, Uwe, Rami S. Komrokji, Pierre Fenaux, et al.. (2022). Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study. Blood. 140(Supplement 1). 1106–1108. 6 indexed citations

10.

Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2022). MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor. Blood. 140(Supplement 1). 6826–6829. 1 indexed citations

11.

Kuykendall, Andrew, Libo Sun, John Mascarenhas, et al.. (2021). Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data. Annals of Hematology. 101(1). 139–146. 18 indexed citations

12.

Platzbecker, Uwe, Rami S. Komrokji, Pierre Fenaux, et al.. (2021). IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.. Journal of Clinical Oncology. 39(15_suppl). TPS7056–TPS7056. 3 indexed citations

13.

Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2021). A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi). Blood. 138(Supplement 1). 1503–1503. 1 indexed citations

14.

Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2020). A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor. Blood. 136(Supplement 1). 43–44. 7 indexed citations

15.

Mascarenhas, John, Rami S. Komrokji, Michèle Cavo, et al.. (2020). Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients. Blood. 136(Supplement 1). 39–40. 9 indexed citations

16.

Platzbecker, Uwe, David P. Steensma, Koen Van Eygen, et al.. (2019). Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood. 134(Supplement_1). 4248–4248. 5 indexed citations

17.

Wang, Lu, et al.. (2018). Diagnosis and treatment of solitary fibrous tumor/hemangiopericytoma of central nervous system. Retrospective report of 17 patients and literature review.. PubMed. 39(2). 88–94. 12 indexed citations

18.

Gao, Lei, Mi Tian, Hongyun Zhao, et al.. (2015). TrkB activation by 7, 8‐dihydroxyflavone increases synapse AMPA subunits and ameliorates spatial memory deficits in a mouse model of Alzheimer's disease. Journal of Neurochemistry. 136(3). 620–636. 61 indexed citations

19.

Pineau, Isabelle, Libo Sun, Dominic Bastien, & Steve Lacroix. (2009). Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion. Brain Behavior and Immunity. 24(4). 540–553. 190 indexed citations

20.

Li, Wei, et al.. (2005). Yeast Model Uncovers Dual Roles of Mitochondria in the Action of Artemisinin. PLoS Genetics. 1(3). e36–e36. 238 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact